Conference Correspondent

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

Immunotherapy is being studied as a potential treatment modality in multiple myeloma (MM). Programmed death 1 (PD-1) receptor and its ligand (PD-L1) is one mechanism of immune evasion by MM to suppress T-cell function. This study was conducted to evaluate whether pembrolizumab, a PD-1–blocking antibody, would enhance the immunomodulatory properties of pomalidomide in heavily pretreated patients with relapsed/refractory MM.

In this phase 2 study, 48 patients with relapsed/refractory MM received 28-day cycles of pembrolizumab 200 mg intravenously every 2 weeks plus pomalidomide (4 mg daily for 21 days) and dexamethasone 40 mg weekly. The study measured safety and efficacy as well as correlation of the CD3/PD-1 on T cells and PD-L1 on plasma cells with response.

The median age of participating patients was 64 years. Patients had a median of 3 lines of prior therapy (range, 2-5). All patients had received both immunomodulatory drugs and proteasome inhibitors, and 72% had prior autologous stem-cell transplantation.

In terms of safety, the most frequently occurring hematologic toxicities (≥grade 3) included neutropenia, anemia, lymphopenia, and thrombocytopenia. The most frequently occurring nonhematologic grade ≥3 events included hyperglycemia, upper respiratory tract infections, fatigue, and rash. Pneumonitis occurred in 6 patients.

Partial response or better was observed in 29 (60%) of 48 patients, including the following: stringent complete response: n = 3, 6%; near complete response: n = 1, 2%; very good partial response (VGPR): n = 9, 19%; and partial response: n = 16, 33%. Additionally, 3 (6%) patients had minimal response, 11 (23%) had stable disease, 2 progressed, and 3 were not evaluable for response. Overall response rate results were also encouraging for double-refractory patients and patients with high-risk cytogenetics. Median duration of response for responding patients was 16.3 months; progression-free survival was 17.4 months; overall survival was not reached. Researchers concluded that the combination of pembrolizumab, pomalidomide, and dexamethasone shows promising durable therapeutic activity and an acceptable safety profile in patients with relapsed/refractory MM.

Badros AZ, et al. ASH 2016. Abstract 490.

Related Items
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: May 17, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME